BIOMAT Database Logo BIOMAT Database Logo

Vincristine, actinomycin D, cyclophosphamide chemotherapy resolves Kasabach-Merritt syndrome resistant to conventional therapies. 2012

Yasushi Fuchimoto, and Nobuyuki Morikawa, and Tatsuo Kuroda, and Seiichi Hirobe, and Shouichiro Kamagata, and Masaaki Kumagai, and Kentaro Matsuoka, and Yasuhide Morikawa
Department of Surgery, Keio University School of Medicine, Tokyo, Japan. yfuchimo@sc.itc.keio.ac.jp

UI MeSH Term Description Entries
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D008297 Male Males
D010976 Platelet Count The number of PLATELETS per unit volume in a sample of venous BLOOD. Blood Platelet Count,Blood Platelet Number,Platelet Number,Blood Platelet Counts,Blood Platelet Numbers,Count, Blood Platelet,Count, Platelet,Counts, Blood Platelet,Counts, Platelet,Number, Blood Platelet,Number, Platelet,Numbers, Blood Platelet,Numbers, Platelet,Platelet Count, Blood,Platelet Counts,Platelet Counts, Blood,Platelet Number, Blood,Platelet Numbers,Platelet Numbers, Blood
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D003609 Dactinomycin A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015) Actinomycin,Actinomycin D,Meractinomycin,Cosmegen,Cosmegen Lyovac,Lyovac-Cosmegen,Lyovac Cosmegen,Lyovac, Cosmegen,LyovacCosmegen
D006390 Hemangioendothelioma A neoplasm derived from blood vessels, characterized by numerous prominent endothelial cells that occur singly, in aggregates, and as the lining of congeries of vascular tubes or channels. Hemangioendotheliomas are relatively rare and are of intermediate malignancy (between benign hemangiomas and conventional angiosarcomas). They affect men and women about equally and rarely develop in childhood. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1866) Endothelioma, Vascular,Hemangio-Endothelioma,Endotheliomas, Vascular,Hemangio Endothelioma,Hemangio-Endotheliomas,Hemangioendotheliomas,Vascular Endothelioma,Vascular Endotheliomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy
D000972 Antineoplastic Agents, Phytogenic Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. Antineoplastics, Botanical,Antineoplastics, Phytogenic,Agents, Phytogenic Antineoplastic,Botanical Antineoplastics,Phytogenic Antineoplastic Agents,Phytogenic Antineoplastics
D012514 Sarcoma, Kaposi A multicentric, malignant neoplastic vascular proliferation characterized by the development of bluish-red cutaneous nodules, usually on the lower extremities, most often on the toes or feet, and slowly increasing in size and number and spreading to more proximal areas. The tumors have endothelium-lined channels and vascular spaces admixed with variably sized aggregates of spindle-shaped cells, and often remain confined to the skin and subcutaneous tissue, but widespread visceral involvement may occur. Kaposi's sarcoma occurs spontaneously in Jewish and Italian males in Europe and the United States. An aggressive variant in young children is endemic in some areas of Africa. A third form occurs in about 0.04% of kidney transplant patients. There is also a high incidence in AIDS patients. (From Dorland, 27th ed & Holland et al., Cancer Medicine, 3d ed, pp2105-7) HHV-8 is the suspected cause. Kaposi Sarcoma,Kaposi's Sarcoma,Multiple Idiopathic Pigmented Hemangiosarcoma,Kaposis Sarcoma,Sarcoma, Kaposi's

Related Publications

Yasushi Fuchimoto, and Nobuyuki Morikawa, and Tatsuo Kuroda, and Seiichi Hirobe, and Shouichiro Kamagata, and Masaaki Kumagai, and Kentaro Matsuoka, and Yasuhide Morikawa
Kasabach-Merritt syndrome-associated kaposiform hemangioendothelioma successfully treated with cyclophosphamide, vincristine, and actinomycin D.
January 1998, Journal of pediatric hematology/oncology,
Yasushi Fuchimoto, and Nobuyuki Morikawa, and Tatsuo Kuroda, and Seiichi Hirobe, and Shouichiro Kamagata, and Masaaki Kumagai, and Kentaro Matsuoka, and Yasuhide Morikawa
Sirolimus for Vincristine-Resistant Kasabach-Merritt Phenomenon: Report of Eight Patients.
May 2017, Pediatric dermatology,
Yasushi Fuchimoto, and Nobuyuki Morikawa, and Tatsuo Kuroda, and Seiichi Hirobe, and Shouichiro Kamagata, and Masaaki Kumagai, and Kentaro Matsuoka, and Yasuhide Morikawa
Vincristine-resistant Kasabach-Merritt phenomenon successfully treated with low-dose radiotherapy.
January 2011, International journal of hematology,
Yasushi Fuchimoto, and Nobuyuki Morikawa, and Tatsuo Kuroda, and Seiichi Hirobe, and Shouichiro Kamagata, and Masaaki Kumagai, and Kentaro Matsuoka, and Yasuhide Morikawa
Kasabach-Merritt syndrome with partial resection of tumor, reduction of tumor blood, and vincristine chemotherapy.
January 2010, The Journal of craniofacial surgery,
Yasushi Fuchimoto, and Nobuyuki Morikawa, and Tatsuo Kuroda, and Seiichi Hirobe, and Shouichiro Kamagata, and Masaaki Kumagai, and Kentaro Matsuoka, and Yasuhide Morikawa
Kasabach-Merritt syndrome: case reports of successful treatment with partial tumor resection and vincristine chemotherapy.
September 2010, Annals of plastic surgery,
Yasushi Fuchimoto, and Nobuyuki Morikawa, and Tatsuo Kuroda, and Seiichi Hirobe, and Shouichiro Kamagata, and Masaaki Kumagai, and Kentaro Matsuoka, and Yasuhide Morikawa
[Kasabach-Merritt syndrome].
October 1994, Ugeskrift for laeger,
Yasushi Fuchimoto, and Nobuyuki Morikawa, and Tatsuo Kuroda, and Seiichi Hirobe, and Shouichiro Kamagata, and Masaaki Kumagai, and Kentaro Matsuoka, and Yasuhide Morikawa
[Kasabach-Merritt syndrome].
November 1974, Gaceta medica de Mexico,
Yasushi Fuchimoto, and Nobuyuki Morikawa, and Tatsuo Kuroda, and Seiichi Hirobe, and Shouichiro Kamagata, and Masaaki Kumagai, and Kentaro Matsuoka, and Yasuhide Morikawa
Kasabach-Merritt syndrome.
January 2008, JBR-BTR : organe de la Societe royale belge de radiologie (SRBR) = orgaan van de Koninklijke Belgische Vereniging voor Radiologie (KBVR),
Yasushi Fuchimoto, and Nobuyuki Morikawa, and Tatsuo Kuroda, and Seiichi Hirobe, and Shouichiro Kamagata, and Masaaki Kumagai, and Kentaro Matsuoka, and Yasuhide Morikawa
[Kasabach-Merritt syndrome].
October 2015, La Revue du praticien,
Yasushi Fuchimoto, and Nobuyuki Morikawa, and Tatsuo Kuroda, and Seiichi Hirobe, and Shouichiro Kamagata, and Masaaki Kumagai, and Kentaro Matsuoka, and Yasuhide Morikawa
[Kasabach-Merritt syndrome].
July 1970, Wiadomosci lekarskie (Warsaw, Poland : 1960),
Copied contents to your clipboard!